Galderma Pioneers NDA Path Into OTC Acne Treatment Market
This article was originally published in The Rose Sheet
Executive Summary
FDA on July 8 announces approval for Galderma Laboratories to market Differin Gel 0.1% (adapalene) as an OTC, once-daily topical acne treatment for consumers 12 years old and up.